Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)

Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)
J Figueras AloyComité de Estándares de la Sociedad Española de Neonatología

Abstract

Late preterm infants (32(1) to 35(0) weeks gestation) aged less than 6 months at start of RSV station or discharged during this time may benefit from RSV monoclonal antibodies (palivizumab) administration to decrease the rates of RSV hospitalization. The Spanish Society of Neonatology considers, based on FLIP2 results in Spain, that palivizumab prophylaxis is strongly recommended if the "2 major risk factors" are present (chronological age less than 10 weeks at start of RSV season or being born during its first 10 weeks; sibling of school age or attending day-care assistance). Palivizumab is also recommended when "1 major risk factor and the 2 minor risk factors" are present. Minor risk factors are: mother smoking during pregnancy and being a male.

References

May 12, 2000·American Journal of Respiratory and Critical Care Medicine·N SigursB Kjellman
Aug 14, 2002·Journal of Paediatrics and Child Health·A M VogelM Schousboe
Apr 3, 2003·The Pediatric Infectious Disease Journal·Fernando D Martinez
Dec 5, 2003·Pediatrics·UNKNOWN American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Nov 2, 2004·American Journal of Respiratory and Critical Care Medicine·Nele SigursBengt Kjellman
Jun 26, 2007·The Journal of Pediatrics·Eric A F SimoesUNKNOWN Palivizumab Long-Term Respiratory Outcomes Study Group
Jul 17, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·X Carbonell-EstranyM Lanari
Feb 7, 2009·The New England Journal of Medicine·Caroline Breese HallPeter Szilagyi

❮ Previous
Next ❯

Citations

Dec 29, 2011·European Journal of Pediatrics·B PaesK L Lanctôt
May 2, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B PaesUNKNOWN CARESS Investigators
Aug 12, 2014·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·J A Hurtado SuazoX Demestre Guasch
Jul 23, 2014·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Xavier Carbonell-EstranyJose Figueras-Aloy
May 23, 2012·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·J Duran CarvajalJ Figuerola Mulet
Feb 1, 2011·Early Human Development·Bernhard Resch, Bosco Paes
Dec 19, 2009·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·I Méndez RubioUNKNOWN Grupo IRIS
Apr 10, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M CetinkayaY Yesil
May 5, 2012·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Vanesa MatíasJesus F Bermejo-Martin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.